Isomorphic Labs Raises $5bn in Series C
The AI drug discovery company, spun out of Google DeepMind, closed its latest funding round co-led by Greenoaks and Sequoia.
Updated on Nov. 17, 2026 in Biotech

Live Poll
Do you trust AI to help develop safe new medicines?
Isomorphic Labs has raised a $5bn Series C funding round, co-led by Greenoaks and Sequoia, with participation from Andreessen Horowitz, Thrive Capital, Alphabet, Alphabet's GV and CapitalG, Tamesek, and the Sovereign AI fund. The round follows a $2.1bn Series B raised six months earlier.
Why it matters
The funding will support the company's AI advancement and clinical development infrastructure as it works toward moving its drug candidates into clinical trials. The raise underscores investor interest in applying AI to drug design.
The Series C round is more than twice the size of the Series B raised six months earlier at $2.1bn. Details on valuation and the timeline for advancing candidates into clinical trials have not been disclosed.
The players
Isomorphic Labs
An AI drug discovery company spun out of Google DeepMind that is developing treatments for cancer and immune disorders.
Demis Hassabis
The founder of Isomorphic Labs and a leading figure in AI research, known for co-founding Google DeepMind and leading the development of AlphaFold.
Greenoaks
A growth-stage investment firm that co-led the Isomorphic Labs Series C round.
Sequoia
A prominent venture capital firm that co-led the Isomorphic Labs Series C round.
The details
Isomorphic Labs was founded by Demis Hassabis and spun out of Google DeepMind. The company builds on software developed by DeepMind, including AlphaFold, which predicts protein structures, and is researching treatments for cancer and immune disorders while scaling its proprietary drug design engine, IsoDDE.
Timeline
Six months before the new round: Isomorphic Labs raised $2.1bn in Series B funding.
November 17, 2026: Isomorphic Labs announced its $5bn Series C funding round.
Big Picture
The raise extends the lineage of AlphaFold's protein structure prediction work into commercial drug design, turning a research breakthrough into a funded pipeline of AI-designed therapeutic candidates.
For patients with cancer and immune disorders, the funding signals that AI-designed candidates may reach clinical trials, though no timeline has been set. Readers tracking biotech investment can note the scale of capital now flowing into AI-driven drug design.
The takeaway
Large, rapid funding rounds show that investors are betting heavily on AI to shorten the path from protein research to drug candidates, though outcomes will depend on clinical results still to come.
Further reading
Explore more Biotech coverage for context on AI-driven drug discovery and the companies working in this space.
Live Poll
Do you trust AI to help develop safe new medicines?



